
ATOS
Healthcare · Biotechnology · $19.6M market cap
$1.96+0.02 (+1.0%)Nov 13, 4:13 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +29.1% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2026 | Before the open | -0.86 | -0.56 | +34.9% |
| Aug 7, 2026 | Time not confirmed | -1.04 | -0.95 | +8.7% |
| May 8, 2026 | Before the open | -1.22 | -1.11 | +9.0% |
| Mar 26, 2026 | Time not confirmed | -1.14 | -1.34 | -17.2% |
| Nov 12, 2025 | Before the open | -1.00 | -1.05 | -5.0% |
| Aug 12, 2025 | Before the open | -0.85 | -1.05 | -23.5% |
| May 13, 2025 | Before the open | -0.82 | -0.75 | +8.5% |
| Mar 31, 2025 | Before the open | -0.06 | -0.05 | +21.0% |
| Nov 12, 2024 | Before the open | -0.90 | -0.90 | 0.0% |
| Aug 12, 2024 | Before the open | -0.90 | -0.75 | +16.7% |
| May 13, 2024 | Before the open | -1.00 | -0.75 | +25.0% |
| Mar 28, 2024 | Before the open | -0.06 | -0.09 | -50.0% |
| Nov 13, 2023 | Before the open | -1.00 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other…
| -0.75 |
| +25.0% |
| Aug 14, 2023 | Before the open | -0.90 | -1.20 | -33.3% |
| May 15, 2023 | Before the open | -0.06 | -0.05 | +16.7% |
| Mar 22, 2023 | After the close | -0.97 | -0.90 | +7.2% |
| Nov 7, 2022 | After the close | -0.82 | -0.90 | -9.8% |
| Aug 8, 2022 | After the close | -0.90 | -0.75 | +16.7% |
| May 9, 2022 | After the close | -0.90 | -0.60 | +33.3% |
| Feb 28, 2022 | After the close | -0.04 | -0.04 | 0.0% |
| Nov 15, 2021 | Before the open | -0.82 | -0.60 | +26.8% |
| Aug 13, 2021 | Before the open | -0.52 | -0.90 | -73.1% |
| May 14, 2021 | Before the open | -0.75 | -0.60 | +20.0% |
| Mar 31, 2021 | Before the open | -0.27 | -0.88 | -225.9% |
| Nov 13, 2020 | Before the open | -5.17 | -5.10 | +1.4% |
| Aug 13, 2020 | Before the open | -4.20 | -6.45 | -53.6% |
| May 13, 2020 | Before the open | -0.39 | -0.32 | +17.9% |
| Mar 26, 2020 | Before the open | -4.95 | -3.90 | +21.2% |
| Nov 13, 2019 | Before the open | -7.80 | -5.40 | +30.8% |
| Aug 13, 2019 | Before the open | -7.20 | -12.00 | -66.7% |
| May 13, 2019 | After the close | — | -0.62 | — |
| Mar 28, 2019 | After the close | -9.37 | -18.75 | -100.1% |
| Nov 13, 2018 | After the close | -8.47 | -9.60 | -13.3% |
| Aug 13, 2018 | After the close | -8.32 | -43.50 | -422.8% |
| May 14, 2018 | Before the open | -0.86 | -0.71 | +17.4% |
| Mar 8, 2018 | After the close | -12.60 | 34.20 | +371.4% |